The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.
 
James Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Amod Sarnaik
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - B4CC; Defined Health; Gerson Lehrman Group; Guidepoint Global; Iovance Biotherapeutics
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics
 
Jason Alan Chesney
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals; Mazor Robotics
Honoraria - Sanofi
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Immunocore; Incyte; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Elsevier; Harbour BioMed; Iovance Biotherapeutics; Istari Oncology; Novartis; OncoSec; Pfizer; Scopus BioPharma
Speakers' Bureau - BMS
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; CytomX Therapeutics; Neximmune; Protean Biodiagnostics
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Regeneron; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Protean Biodiagnostics; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Theresa Michelle Medina
Consulting or Advisory Role - Bristol Meyer Squibb; Iovance Biotherapeutics
Research Funding - BioAtla (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Replimune (Inst)
 
Harriet M. Kluger
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Celldex; Clinigen Group; ElevateBio; ElevateBio; Immunocore; Instil Bio; Iovance Biotherapeutics; Merck; Nektar; Shionogi
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Novartis; Pfizer
 
Evidio Domingo-Musibay
Honoraria - Regeneron
Consulting or Advisory Role - Castle Biosciences; Sanofi/Regeneron
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Clinigen Group (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst)
 
Judit Olah
No Relationships to Disclose
 
Eric D. Whitman
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Eisai; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Provectus (Inst); Toray Industries (Inst); Toray Industries (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Salvador Martin-Algarra
Consulting or Advisory Role - AstraZeneca (I); MSD Oncology; Regeneron; Sanofi
Speakers' Bureau - AstraZeneca (I); Bristol-Myers Squibb; MSD (I); MSD Oncology; Novartis; Roche; Roche (I); Sanofi/Regeneron
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche (I)
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Microbiotica; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Halozyme (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Jose Lutzky
Consulting or Advisory Role - Castle Biosciences; Iovance Biotherapeutics; Regeneron; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); Vyriad (Inst)
 
Wen Shi
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Renee Xiao Wu
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Maria Fardis
Employment - Acerta Pharma; Iovance Biotherapeutics
Leadership - Acerta Pharma; Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie; Acerta Pharma; Gilead Sciences; Iovance Biotherapeutics; Kartos Therapeutics
Patents, Royalties, Other Intellectual Property - Acerta Pharma (Inst); Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; Iovance Biotherapeutics
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)